NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) today announced physician experience from a large cohort of epilepsy patients treated with its OneRF Ablation System at the Mayo Clinic in Jacksonville, Florida, highlighting a potential paradigm shift in the treatment of drug-resistant focal epilepsy. The team, led by neurologist Dr. Brin Freund and the late neurosurgeon Dr. Sanjeet Grewal, performed radiofrequency (RF) ablations on 25 patients using NeuroOne's stereo-EEG (SEEG) electrodes for both diagnosis and treatment.
According to the company, the procedure was well tolerated with rare short-term effects and no serious long-term complications. The majority of patients experienced meaningful reductions in seizure frequency, with some achieving sustained seizure freedom either directly after RF ablation or following subsequent surgical or medical therapy guided by data from the ablation. Most patients also reported improved quality of life and satisfaction with the procedure. Ablation targets ranged from small, discrete seizure areas to multifocal or more extensively distributed epileptic networks.
“NeuroOne SEEG-guided radiofrequency thermocoagulation is a minimally invasive procedure that can be performed at the bedside through the same implanted diagnostic electrodes used to localize a patient's seizures,” said Dr. Freund. “After recording seizures and mapping critical brain regions, we can precisely target seizure-generating tissue while preserving normal brain function. An important advantage is its ability to deliver a controlled, temperature-based treatment while allowing us to immediately resume recording afterward, enabling real-time assessment and additional targeted ablations during the same monitoring period. This approach has changed how we treat drug-resistant focal epilepsy and is now part of the standard of care at Mayo Clinic Florida.”
This real-world evidence underscores the growing adoption of a diagnosis-to-therapy paradigm, where the same implanted electrodes used for diagnostic SEEG monitoring can also deliver therapeutic ablation. NeuroOne's OneRF System is the only FDA-cleared platform combining SEEG diagnosis and RF ablation using the same sEEG device, according to the company. The system's proprietary temperature monitoring technology provides physicians with real-time treatment feedback, adding a layer of confidence during the procedure.
“These results validate our long-held belief that, for patients already undergoing diagnostic SEEG, the ability to potentially deliver meaningful therapeutic benefit through the same implanted electrodes represents a compelling clinical and economic value proposition,” said Dave Rosa, CEO of NeuroOne. “Importantly, that opportunity is enabled by our proprietary temperature monitoring technology, which provides physicians with real-time treatment feedback and an additional layer of confidence during ablation.”
The implications of this announcement are significant for the estimated 30% of epilepsy patients who are drug-resistant and may require surgical intervention. Traditional surgical resection is invasive and carries risks, whereas the OneRF approach offers a minimally invasive bedside procedure that can be performed during the same monitoring period. This could reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions in a single device. For more information, visit nmtc1.com.
NeuroOne's technology platform includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
